GENOME ANNOUNCEMENT
===================

Ebola virus (EBOV) causes a severe hemorrhagic fever with case fatality rates of up to 90% ([@B1]). Currently, no vaccines or therapeutics are approved for use in humans, although a number of promising experimental vaccines and treatment options exist ([@B2]). In the past, EBOV outbreaks have been restricted to central Africa ([@B3]); however, in December 2013, EBOV emerged in West Africa in the province of Gueckedou in Guinea ([@B4]). Since then, it has spread throughout Guinea and into the neighboring countries of Sierra Leone and Liberia, and imported cases have occurred in Senegal, Nigeria, and Mali. This outbreak, which is still ongoing, has affected more people and resulted in a greater number of deaths than all previous outbreaks combined (13,268 cases and 4,960 deaths as of 7 November 2014; <http://apps.who.int/iris/bitstream/10665/137592/1/roadmapsitrep_7Nov2014_eng.pdf>), and an unprecedented effort by the international community will be necessary to contain it.

We have determined the complete genome sequences, including the genome termini, of three virus isolates originating from Guinea (Ebola virus/*H. sapiens*-tc/GIN/2014/Makona-WPGC05, Ebola virus/*H. sapiens*-tc/GIN/2014/Makona-WPGC07, and Ebola virus/*H. sapiens*-tc/GIN/2014/Makona-WPGC15). These viruses were grown in Vero E6 cells (sequences were derived from p1 stocks) and are now used by a number of high-containment laboratories in North America, making their sequences of interest to these facilities. RNA was extracted from cell supernatant using a viral RNA extraction kit (Qiagen) using protocols approved by the Institutional Biosafety Committee and reverse transcribed using Superscript III (Invitrogen). PCR products of approximately 700 bp in length were amplified using IProof polymerase (Bio-rad) and subjected to conventional Sanger sequencing. Terminal sequences were determined by 5′ and 3′ rapid amplification of cDNA ends (RACE) based on ligation-anchored PCR, as previously described ([@B5][@B6][@B7]). Sequences were assembled using SeqMan Pro (Lasergene; DNAStar), and fragment ends were trimmed to exclude primer sequences.

All three full-length genome sequences showed very high similarities to nearly complete genome sequences of West African EBOVs previously published, although there were between 2 and 4 nucleotide differences to published EBOV sequences from Guinea ([@B4]) and between 7 and 17 nucleotide differences to published EBOV sequences from Sierra Leone ([@B8]). Surprisingly, in addition, the 5′ end of the genomic RNA was very clearly 1 nucleotide shorter than previously reported EBOV genomes, lacking a previously reported terminal U residue. It should be noted that these are the first sequences from the West African EBOV outbreak for which the genome ends were experimentally determined. Sequencing of PCR fragments spanning the 3′ genome end showed two PCR product species, a predominant one in which the 3′ end matched previously published sequences (3′-GCC... sequence in negative orientation) and a minority species that was 1 nucleotide shorter (3′-CC...). These differences in the genome termini compared to previously published sequences might have implications for the mechanism of virus genome replication and warrant further studies.

Nucleotide sequence accession numbers. {#h1}
--------------------------------------

The complete genome sequences of the EBOV isolates WPGC05, WPGC07, and WPGC15 have been submitted to GenBank under the accession numbers [KP096420](KP096420), [KP096421](KP096421), and [KP096422](KP096422).
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